A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03714815 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
91
Enrollment
INDUSTRY
Sponsor class

Stopped the absence of a positive trend in all efficacy parameters indicates that macitentan 10 mg does not have a beneficial effect in patients with HFpEF and PVD.

Conditions

Interventions

Sponsor

Actelion

Collaborators